EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME

(19)

(11)

EP 2 877 159 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	14.02.2018 Bulletin 2018/07

(45)	Mention of the grant of the patent:
	08.11.2017 Bulletin 2017/45

(21)	Application number: 13745549.9

(22)	Date of filing: 26.07.2013

(51)

International Patent Classification (IPC):

A61K 9/14^(2006.01)
A61K 9/51^(2006.01)

A61K 31/473^(2006.01)

(86)	International application number:
	PCT/US2013/052402

(87)	International publication number:
	WO 2014/018932 (30.01.2014 Gazette 2014/05)

(54)	EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME EFFLUX-INHIBITORZUSAMMENSETZUNGEN UND BEHANDLUNGSVERFAHREN DAMIT COMPOSITIONS INHIBITRICES D'ÉCOULEMENT ET MÉTHODES DE TRAITEMENT À L'AIDE CELLES-CI

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

27.07.2012 US 201261676689 P

(43)	Date of publication of application:
	03.06.2015 Bulletin 2015/23

(73)	Proprietor: Izumi Technology, LLC.
	Lexington, MA 02420 (US)

(72)	Inventors:
	VAN TELLINGEN, Olaf NL-1507 TC Zaandam (NL) BUNT, Antonius, Martinus Gustave Lexington, MA 02420 (US)

(74)	Representative: FRKelly
	27 Clyde Road Dublin D04 F838 Dublin D04 F838 (IE)

(56)

References cited: :

US-A1- 2009 170 880

BREEDVELD P ET AL: "The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 7, 1 April 2005 (2005-04-01), pages 2577-2582, XP007901255, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-04-2416
DE VRIES N A ET AL: "P-Glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 21, 1 November 2007 (2007-11-01), pages 6440-6449, XP002502538, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1335

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).